news
New gene therapy could preserve vision in retinitis pigmentosa patients
Delivering Txnip to mice with retinitis pigmentosa was an effective treatment, making this approach a potential gene therapy for the disease.
List view / Grid view
Drug Development
news
Stem cell-derived organoids developed to test SARS-CoV-2 drugs on gut
Induced pluripotent stem cells (iPSC) intestinal organoids have been created to duplicate SARS-CoV-2, enabling drug testing.
article
COVID-19, broad-spectrum therapeutics and the magic blanket paradigm
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
news
Novel PF74-like small molecules developed to target HIV capsid protein
Scientists have developed PF74-like small molecules able to target the HIV-1 capsid protein, identifying four potent compounds.
news
Novel Zika virus vaccine shows success in pre-clinical trials
A new VLP-based Zika virus vaccine is able to protect mice completely from infection, researchers have found.
article
Expanding accessible chemical space through automated high-throughput experimentation
Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.
article
How RNA therapeutics can be used to treat retinitis pigmentosa
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
news
Novel opioid could provide pain relief alternative to fentanyl
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
news
New in vitro assay developed to test potential NASH drugs
An assay that combines 3D disease models and automated AI-based fibrosis quantification could accelerate NASH drug discovery.
article
Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
article
Drug Target Review Vaccine Development ebook 2021
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
news
Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
article
Synthesising very long-chain fatty acids to treat retinal conditions
A class of lipids – or fatty acids – found in the retina of the eye play an important role in maintaining vision. Victoria Rees, Deputy Editor of Drug Target Review, spoke with Dr Paul Bernstein from the Moran Eye Center at the University of Utah, US, to discover how…
article
Which CHO cell is the right CHO cell?
Dr Louis Boon offers guidance on how to select the best CHO cell for the upstream bioprocessing of biologics. He also explains how automation can aid monoclonality and why the most efficient approach during the development of biological drugs is to utilise an established cell line platform.
whitepaper
Product hub: The world’s first BioPharma Lifecycle Management system – navigating your biopharma lifecycle
Here, we present IDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration and insight.